<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371718</url>
  </required_header>
  <id_info>
    <org_study_id>JKB-122 AIH01</org_study_id>
    <nct_id>NCT04371718</nct_id>
  </id_info>
  <brief_title>Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo Controlled, Trial of JKB-122 as an Adjunct Therapy to Prednisolone and Azathioprine in the Induction of Remission in Autoimmune Hepatitis (AIH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiwanJ Pharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TaiwanJ Pharmaceuticals Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study. All patients will receive prednisolone and AZA as standard of care&#xD;
      (SOC) during the study. At the end of the study, all data collected will be analyzed the&#xD;
      efficacy and safety of JKB-122 on SOC reduction and inflammation improvement in Autoimmune&#xD;
      Hepatitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      JKB-122 has been demonstrated effective reducing aminotransferase in refractory AIH patients&#xD;
      with SOC.This is a new Phase 2 study to find an optimal dose for relevant phase 3 study in&#xD;
      newly diagnostic AIH patients. All patients will receive prednisolone and AZA as standard of&#xD;
      care (SOC) during the study. Subjects will be randomized to receive 5 mg JKB-122, 15 mg&#xD;
      JKB-122, 35 mg JKB-122 or placebo in 1:1:1:1 ratio, adjunct to SOC. This protocol with the&#xD;
      primary endpoint being biochemical remission and evaluation of 3 different treatment doses.&#xD;
      The histology will be explored as secondary to test long term benefit and to show similar&#xD;
      trend with the biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of inflammation in Autoimmune Hepatitis</measure>
    <time_frame>6, 12, and 24 months</time_frame>
    <description>The % of patients in each treatment group who achieve biochemical remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steroid sparing effect</measure>
    <time_frame>week 104</time_frame>
    <description>Steroid accumulation dose in overall or in those who achieve resolution of histology without worsening of the fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver histology as measured by Hepatic Activity Index (HAI)</measure>
    <time_frame>Week 104</time_frame>
    <description>The reduction of inflammation in histology refers to improve Autoimmune Hepatitis disease status</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Autoimmune Hepatitis</condition>
  <arm_group>
    <arm_group_label>JKB-122 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JKB-122 5 mg daily for 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JKB-122 Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JKB-122, 15 mg daily for 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JKB-122 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JKB-122 35 mg daily for 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo, daily for 104 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JKB-122</intervention_name>
    <description>JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis</description>
    <arm_group_label>JKB-122 High dose</arm_group_label>
    <arm_group_label>JKB-122 Low dose</arm_group_label>
    <arm_group_label>JKB-122 Medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A capsule has same component but active drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 18 to 65 years old.&#xD;
&#xD;
          2. If female of childbearing potential, must not be pregnant or breastfeeding and either&#xD;
             postmenopausal (no menses for previous 12 months) or using an effective method of&#xD;
             birth control.&#xD;
&#xD;
          3. Probable or definite diagnosis of autoimmune hepatitis according to the International&#xD;
             Autoimmune Hepatitis Study Group criteria.&#xD;
&#xD;
          4. New diagnosis of AIH that requires treatment according to the current EASL guidelines.&#xD;
&#xD;
          5. Has elevated liver test results (ALT) at least 5x ULN at screening.&#xD;
&#xD;
          6. Is capable of understanding and signing the informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Overlap syndrome with Primary Sclerosing Cholangitis (PSC) or Primary Biliary&#xD;
             Cholangitis (PBC)&#xD;
&#xD;
          2. Has cirrhosis on liver biopsy, or Child-Pugh score greater than 6 at screening.&#xD;
&#xD;
          3. Has human immunodeficiency virus (HIV) or is hepatitis B virus or HCV positive.&#xD;
&#xD;
          4. Has history of alcohol intake &gt; 25 g/day within the past six months.&#xD;
&#xD;
          5. Severe anemia, leukopenia , or thrombocytopenia.&#xD;
&#xD;
          6. Known intolerances to prednisolone or azathioprine.&#xD;
&#xD;
          7. Current treatment with prednisone/prednisolone and/or immunosuppressive medication for&#xD;
             an indication other than autoimmune hepatitis&#xD;
&#xD;
          8. Has a known or suspected central nervous system disorder that may predispose to&#xD;
             seizures or lower the seizure threshold&#xD;
&#xD;
          9. Has unstable and uncontrollable hypertension (&gt;180/110 mmHg)&#xD;
&#xD;
         10. Has current malignancy or a history of malignancy (within the past 5 years), except&#xD;
             basal or non-metastatic squamous cell carcinoma of the skin that has been treated&#xD;
             successfully.&#xD;
&#xD;
         11. Has any form of current substance abuse, psychiatric disorder or a condition that, in&#xD;
             the opinion of the Investigator, may invalidate communication with the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying-Chu Shih, PhD</last_name>
    <phone>+88636587721</phone>
    <email>info@TaiwanJ.com</email>
  </overall_contact>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune Hepatitis</keyword>
  <keyword>Orphan Disease</keyword>
  <keyword>Aminotransferase</keyword>
  <keyword>Steroid sparing</keyword>
  <keyword>ALT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

